Clinical trials: Prostate Cancer Detection
Prostate Cancer
Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
This pilot phase I trial studies how well copper Cu 64 TP3805 positron emission tomography (PET) works in detecting prostate cancer in patients with persistently elevated prostate specific antigen (PSA).
- Trial name
- NCT02989623
- Testing
- Copper Cu 64 TP3805, Positron Emission Tomography and Computed Tomography Scan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Comparison of Diagnostic Accuracy of Luminal Index and MP MRI for Accelerated deTEction of Significant Prostate Cancer
Multi-parametric (mp) MRI has now internationally been incorporated as standard of care in the work-up of participants with suspected prostate cancer.
- Trial name
- CLIMATE (NCT05020522)
- Testing
- Luminal Index MRI (LI-MRI), LI-MRI targeted prostate biopsy, Plasma methylation signature (ctMethSig)
- Where
- United Kingdom
- Volunteers
- 702 people
- Sponsor
- University College, London
Prostate Cancer
A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy
he most common method for performing a prostate biopsy procedure is the ultrasound guided transrectal procedure. The information obtained from the standard prostate biopsy is deficient and even misleading.
- Trial name
- NaSBxP01 (NCT01480375)
- Testing
- Smartbx™ system.
- Where
- Israel
- Volunteers
- 524 people
- Sponsor
- UC Care, Ltd.
Prostate Cancer
Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision
The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (csPCa) in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the detection…
- Trial name
- NCT06281769
- Testing
- 3D multi-parametric ultrasound targeted biopsy pathway using PcaVision, MRI targeted biopsy pathway
- Where
- 5 sites in Netherlands
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Diagnoses Disease
Micro-Ultrasound/Magnetic Resonance Imaging 001
Micro-ultrasound is a novel real-time imaging modality which maintains the clinical workflow of conventional ultrasound-guided prostate biopsy, while potentially maintaining a similar ability to detect clinically significant…
- Trial name
- NCT03938376
- Testing
- Micro-Ultrasound guided biopsy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Metastatic Prostate Cancer, Prostatic Neoplasms
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer.
- Conditions
- Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer
- Trial name
- NCT03173924
- Testing
- 18F-NaF, 18F-DCFPyL, 18F-FDG
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
The purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the…
- Trial name
- NCT04809584
- Testing
- F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
- Where
- United States
- Sponsor
- Stanford University
Prostate Cancer
Markers for Early Detection of Prostate Cancer
This study will determine whether certain gene alterations can serve as markers for early detection of prostate cancer. Prostate cancer is often diagnosed by detecting high levels of a protein called prostate-specific antigen…
- Trial name
- NCT00340717
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG
Prostate Cancer
Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy
This phase II trial studies ciprofloxacin compared to an inactive treatment (placebo) in diagnosing prostate cancer in patients undergoing removal of prostate cells or tissues for examination (biopsy).
- Trial name
- NCT02252978
- Testing
- ciprofloxacin, quality-of-life assessment, laboratory biomarker analysis
- Where
- 2 sites in United States
- Sponsor
- Wake Forest University Health Sciences
Prostatic Neoplasms, Prostatic Adenoma
Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique
1. To elucidate the role of CTC detection in the evaluation of risk level in PCa patients, and establish a mathematic model for predicting the pathological status. 2.
- Trial name
- NCT02940977
- Testing
- Blood draws
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer, Prostatic Hyperplasia
Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men
Tranperineal prostate biopsy(TPB) and Transrectal prostate biopsy(TRUSB) are now both routine diagnosis methods of prostate cancer in Queen Mary Hospital.
- Trial name
- NCT04108871
- Testing
- Prostate Biopsy
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- The University of Hong Kong
Prostate, Cancer
Synthetic Metabolic and Genetic Networks for Medical Diagnosics
This is a category 3 human study, prospective, comparative, in parallel groups. A comparative qualitative and quantitative analysis of several markers in 250 samples is proposed.
- Trial name
- SynBioDiag (NCT04518072)
- Testing
- Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
- Where
- 2 sites in France
- Volunteers
- 134 people
- Sponsor
- University Hospital, Montpellier
Prostate Cancer
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa).
- Trial name
- ART-Pro (NCT06579417)
- Testing
- RSI MRI
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 500 people
- Sponsor
- University of California, San Diego
Prostate Cancer
EMBRACE1: Prostate Biorepository
The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for…
- Trial name
- NCT01499381
- Where
- United States
- Volunteers
- 1,290 people
- Sponsor
- Caris Science, Inc.
Prostate Cancer
Choline-PET for Evaluating the Incidence of Nodal Metastases Among Newly Diagnosed Patients of Prostate Cancer
Nodal involvement among patients with prostate cancer is known to be a poor prognostic factor. Traditionally, the presence or absence of nodal disease in patients with prostate cancer is ascertained with the use of anatomical…
- Trial name
- ChoPEN (NCT01769950)
- Testing
- Choline-PET
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Bangalore Institute of Oncology
Brain Cancer, Breast Cancer
18-F-Fluoroacetate as PET Imaging Agent
The goal of this clinical research study is to find out the highest tolerable dose of an imaging solution called 18-F-fluoroacetate sodium that can be given before a positron emission tomography (PET) scan.
- Conditions
- Brain Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01320787
- Testing
- 18F-fluoroacetate
- Sponsor
- M.D. Anderson Cancer Center